SSWM
TEVA icon

Sheets Smith Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sheets Smith Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,100
Closed -$203K – 260
2015
Q4 		$203K Buy
+3,100
New +$192K 0.06% 214

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sheets Smith Wealth Management's TEVA Position: Q1 2016 in Review

Sheets Smith Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 3,100 shares — an estimated $203K sold.

Sheets Smith Wealth Management first reported a position in TEVA in Q4 2015 and held it in 1 quarter. The position peaked at $203K in Q4 2015. 837 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

  • Sheets Smith Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Sheets Smith Wealth Management sold 3,100 Teva Pharmaceuticals shares in Q1 2016, an estimated $203K.
  • Sheets Smith Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Sheets Smith Wealth Management's Teva Pharmaceuticals position peaked at $203K in Q4 2015.
  • 837 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Sheets Smith Wealth Management's 13F filing for Q1 2016, filed 13 May 2016.